Rain Therapeutics to Present at SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Rain Therapeutics Inc. (NASDAQ: RAIN) will present a corporate overview at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 1:40 pm ET. CEO Avanish Vellanki will lead the presentation, followed by a Q&A session. The presentation will be available for replay on the Rain website for 30 days post-event. Rain specializes in precision oncology, targeting oncogenic drivers and selecting patients based on genetic profiles, with its lead candidate being milademetan, an MDM2 inhibitor effective in various cancers.

NEWARK, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview followed by a moderated Q&A at the virtual SVB Leerink 11^th Annual Global Healthcare Conference on Friday, February 18^th at 1:40 pm ET.

Additional details can be found below:

Conference: SVB Leerink Global Healthcare Conference
Date and Time: Friday, February 18^th at 1:40 pm ET.
Registration: Webcast link here.

Replay of the corporate overview presentation and Q&A will be available by visiting the "Events" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com

FAQ

When is Rain Therapeutics' presentation at the SVB Leerink Global Healthcare Conference?

Rain Therapeutics will present on February 18, 2022, at 1:40 pm ET.

Who is presenting for Rain Therapeutics at the conference?

CEO Avanish Vellanki will provide the corporate overview.

How can I access the replay of Rain Therapeutics' presentation?

The replay will be available on the Rain website's 'Events' section for 30 days after the presentation.

What is milademetan developed by Rain Therapeutics?

Milademetan is an oral MDM2 inhibitor targeting various oncogenic cancers.

What type of company is Rain Therapeutics?

Rain Therapeutics is a late-stage precision oncology company focusing on therapies that target oncogenic drivers.